46. Malignant rheumatoid arthritis
4,183 clinical trials,   2,538 drugs   (DrugBank: 401 drugs),   183 drug target genes,   219 drug target pathways

Searched query = "Malignant rheumatoid arthritis", "Rheumatoid arthritis", "Rheumatoid arthritis with vasculitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04196868
(ClinicalTrials.gov)
December 3, 20205/12/2019Methotrexate and Metformin in Rheumatoid Arthritis PatientsRandomized Placebo-controlled Trial Comparing Methotrexate vs. Methotrexate/Metformin Association in Rheumatoid Arthritis PatientsArthritis, RheumatoidDrug: Metformin treatment;Other: Placebo;Drug: Methotrexate treatmentUniversity Hospital, BordeauxMinistry for Health and Solidarity, FranceRecruiting18 YearsN/AAll128Phase 2France
2EUCTR2018-004287-56-FR
(EUCTR)
21/11/201931/01/2020Methotrexate and Metformin in rheumatoid arthritis patientsRandomized placebo-controlled trial comparing Methotrexate vs. Methotrexate/Metformin association in rheumatoid arthritis patients: METorMET² study - METorMET2 rheumatoid arthritis (RA)
MedDRA version: 20.0;Level: HLT;Classification code 10039075;Term: Rheumatoid arthritis and associated conditions;System Organ Class: 100000004870 ;Therapeutic area: Body processes [G] - Immune system processes [G12]
CHU de BordeauxNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
128Phase 2France
3NCT04068246
(ClinicalTrials.gov)
August 1, 201921/8/2019The AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis PatientsThe AMPK Modulator Metformin as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial.Rheumatoid ArthritisDrug: Metformin;Drug: PlaceboSadat City UniversityNULLRecruiting18 YearsN/AAll150Early Phase 1Egypt
4NCT03863405
(ClinicalTrials.gov)
January 9, 20194/3/2019Metformin Use in Rheumatoid ArthritisThe Effect of Metformin on the Clinical Outcome of Patients With Rheumatoid ArthritisRheumatoid ArthritisDrug: Metformin;Drug: Conventional DMARDs;Drug: Placebo Oral TabletAin Shams UniversityFuture University in EgyptRecruiting18 YearsN/AAll60Phase 2Egypt
5ChiCTR-INR-17011772
2017-06-272017-06-28The efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agentsThe efficacy and safety of metformin hydrochloride combined with atorvastatin in the treatment of rheumatoid arthritis with poor response to immunosuppressive agents Rheumatoid Arthritistest group:Metformin tablets, 0.25g, 3 / day, oral, atorvastatin tablets 10mg, 1 / night, oral;;Control group:Traditional DMARDs group;Inner Mongolia University of Science and Technology Baotou Medical College First Affiliated HospitalNULLRecruiting1865Bothtest group:80;Control group:40;China
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6ChiCTR-IPR-17010325
2017-01-312017-01-04The efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trialThe efficacy and safety of Metformin combined with coenzyme Q10 in refractory rheumatoid arthritis: A multi-center randomized controlled trial rheumatic disease;M05.901Metformin Group:Metformin combined Glucocorticoids and DMARDs;Non-Metformin Group:Glucocorticoids and DMARDs;Metformin combined with Coenzyme Q10 Group:Metformin and Coenzyme Q10 combined Glucocorticoids and DMARDs;the Second Hospital of Shanxi Medical UniversityNULLPending1865BothMetformin Group:100;Non-Metformin Group:100;Metformin combined with Coenzyme Q10 Group:100;China
7NCT02246257
(ClinicalTrials.gov)
September 201417/9/2014Early Rheumatoid Arthritis COR InterventionMultifactorial Intervention to Prevent Cardiovascular Disease in Patients With Early Rheumatoid ArthritisRheumatoid Arthritis;Cardiovascular DiseasesOther: Simvastatin;Other: Losartan;Other: Metformin;Other: Outpatient rheumatology department;Other: Refered to general practiceMD, PhD, Annemarie Lyng SvenssonNULLUnknown status18 YearsN/AAll300N/ADenmark
8NCT01405118
(ClinicalTrials.gov)
June 20117/7/2011Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy VolunteersA Phase 1, Open Labeled, Fixed Sequence Study To Estimate The Effect Of CP-690,550 On The Pharmacokinetics Of Metformin In Healthy VolunteersRheumatoid ArthritisDrug: Metformin/CP-690,550PfizerNULLCompleted18 Years55 YearsBoth24Phase 1Belgium